TOMEK, Ales, Petra REKOVÁ, Jaroslava PAULASOVÁ SCHWABOVÁ, Anna OLŠEROVÁ, Miroslav ŠKORŇA, Miroslava NEVŠÍMALOVÁ, Libor ŠIMŮNEK, Roman HERZIG, Štěpánka FAFEJTOVÁ, Petr MIKULENKA, Alena TÁBOŘÍKOVÁ, Jiří NEUMANN, Richard BRZEZNY, Helena SOBOLOVÁ, Jan BARTONÍK, Daniel VÁCLAVÍK, Marta VACHOVÁ, Karel BECHYNĚ, Hana HAVLÍKOVÁ, Tomáš PRAX, Daniel ŠAŇÁK, Irena ČERNÍKOVÁ, Iva ONDEČKOVÁ, Petr PROCHÁZKA, Jan RAJNER, Miroslav ŠKODA, Jan NOVÁK, Ondřej ŠKODA, Mcihal BAR, Robert MIKULÍK, Gabriela DOSTÁLOVÁ and Aleš LINHART. Nationwide screening for Fabry disease in unselected stroke patients. PLOS ONE. SAN FRANCISCO: PUBLIC LIBRARY SCIENCE, 2021, vol. 16, No 12, p. 1-12. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0260601.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nationwide screening for Fabry disease in unselected stroke patients
Authors TOMEK, Ales (203 Czech Republic), Petra REKOVÁ (203 Czech Republic), Jaroslava PAULASOVÁ SCHWABOVÁ (203 Czech Republic), Anna OLŠEROVÁ (203 Czech Republic), Miroslav ŠKORŇA (203 Czech Republic, belonging to the institution), Miroslava NEVŠÍMALOVÁ (203 Czech Republic), Libor ŠIMŮNEK (203 Czech Republic), Roman HERZIG (203 Czech Republic), Štěpánka FAFEJTOVÁ (203 Czech Republic), Petr MIKULENKA (203 Czech Republic), Alena TÁBOŘÍKOVÁ (203 Czech Republic), Jiří NEUMANN (203 Czech Republic), Richard BRZEZNY (203 Czech Republic), Helena SOBOLOVÁ (203 Czech Republic), Jan BARTONÍK (203 Czech Republic), Daniel VÁCLAVÍK (203 Czech Republic), Marta VACHOVÁ (203 Czech Republic), Karel BECHYNĚ (203 Czech Republic), Hana HAVLÍKOVÁ (203 Czech Republic), Tomáš PRAX (203 Czech Republic), Daniel ŠAŇÁK (203 Czech Republic), Irena ČERNÍKOVÁ (203 Czech Republic), Iva ONDEČKOVÁ (203 Czech Republic), Petr PROCHÁZKA (203 Czech Republic), Jan RAJNER (203 Czech Republic), Miroslav ŠKODA (203 Czech Republic), Jan NOVÁK (203 Czech Republic), Ondřej ŠKODA (203 Czech Republic), Mcihal BAR (203 Czech Republic), Robert MIKULÍK (203 Czech Republic, guarantor, belonging to the institution), Gabriela DOSTÁLOVÁ (203 Czech Republic) and Aleš LINHART (203 Czech Republic).
Edition PLOS ONE, SAN FRANCISCO, PUBLIC LIBRARY SCIENCE, 2021, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.752
RIV identification code RIV/00216224:14110/21:00124284
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0260601
UT WoS 000754615500008
Keywords in English Fabry disease; stroke patients; screening
Tags 14110127, 14110221, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/2/2022 13:29.
Abstract
Background and aims Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by disease-associated variants in the alpha-galactosidase A gene (GLA). FD is a known cause of stroke in younger patients. There are limited data on prevalence of FD and stroke risk in unselected stroke patients. Methods A prospective nationwide study including 35 (78%) of all 45 stroke centers and all consecutive stroke patients admitted during three months. Clinical data were collected in the RES-Q database. FD was diagnosed using dried blood spots in a stepwise manner: in males—enzymatic activity, globotriaosylsphingosine (lyso-Gb3) quantification, if positive followed by GLA gene sequencing; and in females GLA sequencing followed by lyso-Gb3. Results 986 consecutive patients (54% men, mean age 70 years) were included. Observed stroke type was ischemic 79%, transient ischemic attack (TIA) 14%, intracerebral hemorrhage (ICH) 7%, subarachnoid hemorrhage 1% and cerebral venous thrombosis 0.1%. Two (0.2%, 95% CI 0.02–0.7) patients had a pathogenic variant associated with the classical FD phenotype (c.1235_1236delCT and p.G325S). Another fourteen (1.4%, 95% CI 0.08–2.4) patients had a variant of GLA gene considered benign (9 with p.D313Y, one p.A143T, one p.R118C, one p.V199A, one p.R30K and one p.R38G). The index stroke in two carriers of disease-associated variant was ischemic lacunar. In 14 carriers of GLA gene variants 11 strokes were ischemic, two TIA, and one ICH. Patients with positive as compared to negative GLA gene screening were younger (mean 60±SD, min, max, vs 70±SD, min, max, P = 0.02), otherwise there were no differences in other baseline variables. Conclusions The prevalence of FD in unselected adult patients with acute stroke is 0.2%. Both patients who had a pathogenic GLA gene variant were younger than 50 years. Our results support FD screening in patients that had a stroke event before 50 years of age.
Links
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 24/4/2024 14:25